Over the last 12 months, Roivant Sciences insiders reported no purchases and 9 sales totaling $203.8M across SEC Form 4 filings. 44% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 200,000 | $34.95 | $7.0M | -11% | plan |
| Jun 30, 2026 | Fitzgerald MeghanD | ▼ Sale | 10,000 | $34.9 | $349K | -18.9% | plan |
| Jun 30, 2026 | MANCHESTER KEITH SD | ▼ Sale | 200,000 | $35.45 | $7.1M | -10.3% | — |
| Jun 30, 2026 | MANCHESTER KEITH SD | ▼ Sale | 1,438,163 | $34.32 | $49.4M | -9.5% | 5 tranches · indirect |
| Jun 30, 2026 | Gold Daniel AllenD | ▼ Sale | 1,438,163 | $34.32 | $49.4M | -9.5% | 5 tranches · indirect |
| Jun 30, 2026 | QVT Financial LP | ▼ Sale | 1,438,163 | $34.32 | $49.4M | -9.5% | 5 tranches · indirect |
| Jun 29, 2026 | Epperly Melissa B,D | ▼ Sale | 17,750 | $34.38 | $610K | -51.9% | plan · 2 tranches |
| Jun 26, 2026 | Sukhatme MayukhPresident & CIO · O·D | ▼ Sale | 1,000,000 | $34.1 | $34.1M | -5.1% | 2 tranches |
| Jun 24, 2026 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 200,000 | $33.16 | $6.6M | -11% | plan · 2 tranches |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ROIV feed.